Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (274)

« Back to Publications

T cell engagers: expanding horizons in oncology and beyond.

Albayrak G. et al, (2025), Br J Cancer, 133, 1241 - 1249

Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.

Baugh R. et al, (2024), J Immunother Cancer, 12

The British Society for Gene and Cell Therapy at 20 (2003-2023).

Seymour L. et al, (2024), Hum Gene Ther, 35, 5 - 8

Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?

Wan PK-T. et al, (2023), J Immunother Cancer, 11

Optogenetically Engineered Neurons Differentiated from Human SH-SY5Y Cells Survived and Expressed ChR2 in 3D Hydrogel.

Lee S-Y. et al, (2022), Biomedicines, 10

Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination.

Su W. et al, (2022), Nat Commun, 13

Deregulation of HLA-I in cancer and its central importance for immunotherapy.

Hazini A. et al, (2021), J Immunother Cancer, 9

Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus.

Wan PK-T. et al, (2021), Mol Ther, 29, 1668 - 1682

Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.

Khalique H. et al, (2021), J Immunother Cancer, 9

Tackling HLA Deficiencies Head on with Oncolytic Viruses.

Fisher K. et al, (2021), Cancers (Basel), 13

Development of a novel mammalian display system for selection of antibodies against membrane proteins.

Robertson N. et al, (2020), J Biol Chem, 295, 18436 - 18448

Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response.

Baugh R. et al, (2020), Cancers (Basel), 12

The role of cancer metabolism in defining the success of oncolytic viroimmunotherapy

DYER A. et al, (2020), Cytokine and Growth Factor Reviews

A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR).

O'Cathail SM. et al, (2020), Radiat Oncol, 15

Attenuation of the Hypoxia Inducible Factor Pathway after Oncolytic Adenovirus Infection Coincides with Decreased Vessel Perfusion.

Yousaf I. et al, (2020), Cancers (Basel), 12

Load More

1
2
3
4
5
6
7
...
»